AMT-116 by Multitude therapeutics for Head And Neck Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMT-116 overview

AMT-116 is under development for the treatment of non-small cell lung cancer, head and neck cancer, colorectal cancer, triple-negative breast cancer (TNBC), esophageal cancer, pancreatic cancer, colorectal cancer, cervical cancer, breast cancer, bladder cancer, gastric cancer, biliary tract cancer, skin squamous cell cancer, gastric cancer, liver cancer, and basal cell cancer. It is an antibody-drug conjugate and is being developed based on MabArray technology. it is administered parenterally through intravenous route.

Multitude therapeutics overview

Multitude therapeutics is a Pharmaceuticals and Healthcare company that Develop antibody-drug conjugates. The company is headquartered in Redwood city, California, The U.S.

For a complete picture of AMT-116’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.